Pricing Log in Create free account
Friday 6 November 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue
+1.44%
EPS
−21.6%
Free cash flow
−25.3%
Total debt
+3.04%

Quarter to September 2026, against a year earlier

42.73 1.91 −4.28%
Market cap
$64.7B
P/E
18.7×
Fwd P/E
17.0×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Boston Scientific Corporation 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 6:32 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: 22 added · 7 removed · 37 modified; 8 with only figures updated

  1. Modified · Three Months Ended June 30, 2025

    Our net sales for the firstsecond quarter of 2025 were $4.6635.061 billion, compared to $3.8564.120 billion for the firstsecond quarter of 2024. This increase of $806941 million, or 20.922.8 percent, included operational1 net sales growth of 22.221.6 percent and the negativepositive impact of 130120 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 18.217.4 percent and the positive impact of 400420 basis points from certain acquisitions during the period for which there are less than a full period of comparable net sales. In 2024, Those acquisitions included the endoluminal vacuum therapy portfolio of B. Braun Medical Inc. (Braun), Silk Road Medical, Inc. (Silk Road Medical) and Axonics, Inc. (Axonics), during the first, third and fourth quarters of 2024, respectively. There were no applicable acquisitions in, and Intera Oncology®, Inc. (Intera) during the firstsecond quarter of 2025. The increase in our net sales was primarily driven by strong commercial execution across our businesses, particularly in our Electrophysiology business unit, which was led by the rapid adoption of our FarapulseTM Pulsed Field Ablation System which launched in the U.S. in 2024. Refer to Quarterly Results and Business Overview for a discussion of our net sales by business.